Pioglitazone and vitamin E for nonalcoholic steatohepatitis: A cost utility analysis
نویسندگان
چکیده
منابع مشابه
Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis.
UNLABELLED Nonalcoholic steatohepatitis (NASH) is the commonest liver disease in developed countries. However, there are no current data on the cost-effectiveness of therapeutic options such as lifestyle modification, pioglitazone, or vitamin E. We undertook a cost utility analysis to compare these strategies. Using a third-party payer perspective, a deterministic Markov model was developed to ...
متن کاملPioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
BACKGROUND Nonalcoholic steatohepatitis is a common liver disease that can progress to cirrhosis. Currently, there is no established treatment for this disease. METHODS We randomly assigned 247 adults with nonalcoholic steatohepatitis and without diabetes to receive pioglitazone at a dose of 30 mg daily (80 subjects), vitamin E at a dose of 800 IU daily (84 subjects), or placebo (83 subjects)...
متن کاملPioglitazone in nonalcoholic steatohepatitis.
*KURAに登録されているコンテンツの利用については,著作権法に規定されている私的使用や引用などの範囲内で行ってください。 *著作権法に規定されている私的使用や引用などの範囲を超える利用を行う場合には,著作権者の許諾を得てください。ただし,著作権者 から著作権等管理事業者(学術著作権協会,日本著作出版権管理システムなど)に権利委託されているコンテンツの利用手続については ,各著作権等管理事業者に確認してください。 Title Pioglitazone in Nonalcoholic Steatohepatitis Author(s) Ota, Tsuguhito; Takamura, Toshinari; Kaneko, Shuichi Citation New England Journal of Medicine, 356(10): 1067-1069 Issue Date 20...
متن کاملA pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.
Nonalcoholic steatohepatitis (NASH) is a common chronic liver disease for which there is no known effective therapy. A proportion of patients with NASH progress to advanced fibrosis and cirrhosis. NASH is considered one of the clinical features of the metabolic syndrome in which insulin resistance plays a central role. This prospective study evaluates the role of insulin-sensitizing agent in tr...
متن کاملEfficacy of Vitamin E and Vitamin C in the Treatment of Nonalcoholic Steatohepatitis
INTRODUCTION Nonalcoholic steatohepatitis (NASH), a subset of nonalcoholic fatty liver disease (NAFLD), is becoming an increasing health concern, with current data showing the prevalence in the United States to range between 5.7%–16.5% (1,2). Patients with NASH lack a history of significant alcohol consumption, but liver biopsy findings are almost identical to biopsy findings in patients with a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Hepatology
سال: 2012
ISSN: 0270-9139
DOI: 10.1002/hep.25887